Management of motor complications in advanced Parkinson's disease

Movement Disorders

Volumn 22, Issue SUPPL. 17, 2007, Pages

  Melamed, Eldad ^a,b   Ziv, Ilan ^c   Djaldetti, Ruth ^c  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c NONE

Author keywords

Delayed on; Levodopa; Motor fluctuations; No on; On off; Wearing off

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOMPERIDONE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LISURIDE; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; TOLCAPONE;

ALLERGIC REACTION; BRAIN DEPTH STIMULATION; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED RELEASE FORMULATION; DECARBOXYLATION; DRUG EFFECT; DRUG EFFICACY; DYSKINESIA; HEART PALPITATION; HOT FLUSH; HUMAN; LIVER TOXICITY; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NAUSEA; ORTHOSTATIC HYPOTENSION; PALLIDOTOMY; PANIC; PARANOIA; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; SWEATING; THALAMOTOMY; TREATMENT RESPONSE; VISUAL HALLUCINATION;

COMBINED MODALITY THERAPY; CORPUS STRIATUM; DEEP BRAIN STIMULATION; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FETAL STEM CELLS; HUMANS; LEVODOPA; MOVEMENT DISORDERS; NEUROSURGICAL PROCEDURES; PARKINSON DISEASE; QUALITY OF LIFE; RECEPTORS, DOPAMINE; SUBSTANTIA NIGRA; THALAMUS;

EID: 36248950146     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21680     Document Type: Conference Paper

References (41)

1. Melamed E. L-Dopa. In: Adelman G, editor. Encyclopedia of neuroscience. Cambridge: Birkhauser-Boston; 1987. p 553-554.
2. Steiger NJ, Quinn NP. Levodopa-based therapy. In: Koller WC, editor. Handbook of Parkinson's disease. New York: Marcel Dekker; 1992. p 391-410.
3. Marsden CD, Parkes JD, Quinn NP. Fluctuations of disability in Parkinson's disease - clinical aspects. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworth; 1982. p 96-122.
4. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease: a clinical and neuropharmacological study. Brain 1984;107:487-506.
5. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1997;1:345-349.
6. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-681.
7. Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993;43:1459-1464.
8. Melamed E, Bitton V. Delayed onset of responses to individual doses of levodopa in parkinsonian fluctuators on long-term L-dopa therapy. Clin Neuropharmacol 1986;9:182-186.
9. Melamed E, Bitton V, Zelig O. Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators. Neurology 1986;36:1001-1003.
10. Lesser RP, Fahn S, Snider SR, Cote L. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979;29:1253-1266.
11. Nutt JG. Levodopa-induced dyskinesia: review, observations and speculations. Neurology 1990;40:340-345.
12. Hefti F, Melamed E. L-Dopa's mechanism of action in Parkinson's disease. Trends Neurosci 1980;3:229-231.
13. Nutt JG. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987;22:535-540.
14. Wooten GF. Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease. Ann Neurol 1988;24:363-365.
15. Fabrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol 1988;24:366-371.
16. Mouradian MM, Juncos JL, Fabrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neurol 1988;24:372-378.
17. Muenter MD, Tyce GM. L-Dopa therapy of Parkinson's disease: plasma L-dopa concentrations therapeutic response and side effects. Mayo Clin Proc 1971;46:231-239.
18. Fahn S. Episodic failure of absorption of levodopa: a factor in the control of clinical fluctuations in the treatment of parkinsonism. Neurology 1977;27:390-392.
19. Djaldetti R, Ziv I, Melamed E. Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease. Isr J Med Sci 1996;32:1224-1227.
20. Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 1996;46:1051-1054.
21. Waters CH. Managing the late complications of Parkinson's disease. Neurology 1997;49 (suppl 1):S49-S57.
22. Stocchi F, Nordera G, Marsden CD. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 1997;20:95-115.
23. Poewe WH, Lees AJ, Stern GM. Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. Clin Neuropharmacol 1986;9:430-439.
24. Golbe LI, Lieberman AN, Muenter MD, Ahlskog JE, Gopinathan G. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988;11:45-55.
25. Goetz GG, Diedrich NJ. Dopaminergic agonists for the treatment of Parkinson's disease. Neurol Clin 1992;10:527-540.
26. Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993;46:384-393.
27. Jenner P. The rational for use of dopamine agonists in Parkinson's disease. Neurology 1995;45(suppl 3):S6-S12.
28. Stibe CMH, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988;1:403-406.
29. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-0-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1994;44:2685-2688.
30. Kurth MC, Adler CH, Saint-Hillaire M. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter double-blind randomized placebo-controlled trial. Neurology 1997;48:81-87.
31. Rajput AM, Martin W, Saint-Hillaire MH, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing off" phenomenon: a double-blind, placebo-controlled multicenter study. Neurology 1997;49:1066-1071.
32. Kaakkola S, Teravainen H, Ahtila S, Rita H, Gordin A. Effect of entecapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994;44:77-80.
33. Baruzzi A, Cantin M, Riva R. Influence of meal ingestion time on pharmaco-kinetics of orally-administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987;10:527-537.
34. Pincus JH, Barry K. Protein redistribution diet restores motor function in patients with dopa-resistant "off" periods. Neurology 1987;38:481-483.
35. Carter JH, Nutt JH, Woodward WR. Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease. Neurology 1909;39:552-556.
36. Kurth MC, Tetrud LW, Irwin I, Lyness WH, Langston JW. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations - a pilot study. Neurology 1993;43:1036-1039.
37. Djaldetti R, Koren M, Ziv I, Achiron A, Melamed E. Effect of Cisapride on response fluctuations in Parkinson's disease. Mov Disord 1995;10:81-84.
38. Djaldetti R, Melamed E. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Ann Neurol 1996;39:401-404.
39. Olanow CW, Goetz CG, Kordower JH. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-411.
40. Stern MB. Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: an overview. Neurology 1997;49 (suppl 1):S2-S9.
41. Pahwa R, Factor SA, Lyons VE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesias: an evidence-based review. Neurology 2006;66:988-995.